NEWS
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon announced positive results from its Phase 3 trial of ANX005, an immunotherapy targeting C1q for Guillain-Barré Syndrome (GBS). Presented at the 2024 PNS Annual Meeting, data showed faster and more complete recovery for ANX005-treated patients compared to placebo.
Significant improvements were noted in primary and multiple pre-specified endpoints from Week 1 through Week 26. Two and a half times more ANX005-treated patients returned to a normal/pre-disease state of health by Week 26 compared to placebo.
Patients with North American and European baseline characteristics experienced larger benefits in disability and muscle strength measures. A single infusion of ANX005 was generally well-tolerated, with a safety profile similar to placebo.
These findings underscore the potential of ANX005 to become the first targeted immunotherapy for GBS, offering a new treatment option for a significant unmet need in the GBS landscape.
Significant improvements were noted in primary and multiple pre-specified endpoints from Week 1 through Week 26. Two and a half times more ANX005-treated patients returned to a normal/pre-disease state of health by Week 26 compared to placebo.
Patients with North American and European baseline characteristics experienced larger benefits in disability and muscle strength measures. A single infusion of ANX005 was generally well-tolerated, with a safety profile similar to placebo.
These findings underscore the potential of ANX005 to become the first targeted immunotherapy for GBS, offering a new treatment option for a significant unmet need in the GBS landscape.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1075Followers
68Following
7397Visitors
Follow